[ CAS No. 913297-44-6 ] {[proInfo.proName]}

Name: 913297-44-6|7-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one|95%
Brand: Ambeed
SKU: A214455
Price: 13.0 USD
Availability: InStock
Rating: 94 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 913297-44-6

Structure of 913297-44-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 913297-44-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 913297-44-6 ]

SDS Specification

Alternatived Products of [ 913297-44-6 ]

Product Details of [ 913297-44-6 ]

CAS No. :	913297-44-6	MDL No. :	MFCD27932420
Formula :	C₈H₇BrN₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	RTGYXYYWJABYDE-UHFFFAOYSA-N
M.W :	227.06	Pubchem ID :	59635470
Synonyms :

Safety of [ 913297-44-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 913297-44-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 913297-44-6 ]

[ 913297-44-6 ] Synthesis Path-Downstream 1~88

1
[ 1453-58-3 ]
[ 913297-44-6 ]
[ 913298-39-2 ]

Yield	Reaction Conditions	Operation in experiment
	With copper(l) iodide; potassium carbonate; In 1-methyl-pyrrolidin-2-one; at 190℃; for 2h;microwave irradiation;	A suspension of 50 mg (0.220 mmol) of 7-bromo-l- methyl-1, 3-dihydro-2No.-benzimidazol-2-one, 0.035 mL (0.440 mmol) of 3-methylpyrazole, 42 mg (0.0220 mmol) of copper (I) iodide and 61 mg (0.440 mmol) of potassium carbonate in 1 mL of l-methyl-2-pyrrolidinone was stirred by microwave irradiation at 190 0C for 2 hours. After cooling, the reaction mixture was diluted with water and extracted with ethyl acetate (X2). The combined organic layer was washed with brine (Xl) , dried over sodium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with a 25% ethylacetate/n-hexane mixture to give 57 mg of a mixture containing the title EPO <DP n="125"/>compound.1H NMR (CDCl3) delta 2.34 (3H, s) , 2.98 (3H, s) , 6.26 (IH, d, J = 2.2 Hz), 6.97-7.18 (3H, m) , 7.57 (IH, d, J = 2.2 Hz), 9.60 (IH, br s) . MS Calcd. : 228; Found: 229 (M+H) .

Reference： [1]Patent: WO2006/116412,2006,A2 .Location in patent: Page/Page column 123; 124

2
[ 913297-44-6 ]
[ 90002-36-1 ]
[ 913298-33-6 ]

Yield	Reaction Conditions	Operation in experiment
64%	With potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); XPhos; In toluene; at 100℃; for 4h;	mixture of 280 mg (1.23 mmol) of 7-bromo-l-methyl- l,3-dihydro-2No.-benzimidazol-2-one, 222 mg (1.48 mmol) of 2- ethylphenylboronic acid, 113 mg (0.0123 mmol) of tris (dibenzylideneacetone) dipalladium, 29 mg (0.0615 mmol) of X-Phos and 522 mg (2.46 mmol) of potassium phosphate in 9 mL of toluene was stirred at 100 0C for 4 hours. After cooling, the reaction mixture was diluted with water and ethyl acetate and passed through celite. The filtrate was extracted with ethyl acetate (X2) . The combined organic layer was washed with brine (Xl) , dried over sodium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with a 25-65% ethylacetate/n-hexane gradient mixture to give 200 mg (64%) of the title compound. 1H NMR (CDCl3) delta 1.04 (3H, t, J = 7.7 Hz), 2.34-2.52 (2H, m) , 2.84 (3H, s) , 6.86-6.98 (2H, m) , 7.05-7.08 (2H, m) , EPO <DP n="120"/>7.18-7.39 (3H, m), 8.58 (IH, br s). MS Calcd. : 252; Found: 253 (M+H) .

Reference： [1]Patent: WO2006/116412,2006,A2 .Location in patent: Page/Page column 118; 119

3
[ 913297-44-6 ]
[ 913297-43-5 ]

Yield	Reaction Conditions	Operation in experiment
89%	With trichlorophosphate; at 110℃; for 48h;	7-Bromo-l-methyl-l, 3-dihydro-2H-benzimidazol-2-one (2.20 g, 9.69 mmol) was dissolved in phosphorous oxychloride (30 mL) and heated at 1100C for 2 days. The reaction mixture was allowed to cool to room temperature, poured into water with an ice and stirred for 1 h. The mixture was extracted with ethyl acetate, washed with aqueous sodium bicarbonate EPO <DP n="122"/>solution, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography eluting with a 50% ethyl acetate/hexane mixture to give the title compound (2.12 g, 89%) as a white amorphous.1H NMR (CDCl3) delta 3.68 (s, 3H), 6.95 (t, J = 8.1 Hz, IH), 7.03 (d, J = 8.1 Hz, IH), 7.18 (d, J = 8.1 Hz, IH). MS Calcd.: 243; Found: 244 (M+H) .
		7-Bromo-l-methyl-l, 3-dihydro-2H-benzimidazol-2-one (2.20 g, 9.69 mmol) was dissolved in 30 mL of phosphorous oxychloride and the mixture was heated at 110 0C for 2 days. The reaction allowed to cool to room temperature, poured into water with an ice, and stirred for 1 h. The aqueous solution was extracted with ethyl acetate. The extract was washed with aqueous sodium bicarbonate, dried over magnesium sulfate, filtered and concentrated in vacuo to give 2.32 g of the title compound, which was used in the next reaction without further purification. MS Calcd. : 243; Found: 244 (M+H) .

Reference： [1]Patent: WO2008/51533,2008,A2 .Location in patent: Page/Page column 120-121
[2]Patent: WO2006/116412,2006,A2 .Location in patent: Page/Page column 103

4
[ 851886-92-5 ]
[ 913297-44-6 ]

Yield	Reaction Conditions	Operation in experiment
42%	With tert.-butylnitrite; copper(ll) bromide; In N,N-dimethyl-formamide; at 0 - 20℃; for 8h;	To a suspension of compound 5 (6.10 g, 37.4 mmol) and copper(II) bromide (4.20 g, 19.0 mmol) in N,N-dimethylformamide (30 mL) was added tert-butyl nitrite (5.43 mL, 41.1 mmol) at 0 C, and the mixture was stirred at room temperature for 8 h. The reaction mixture was passed through celite, and the filtrate was extracted with ethyl acetate. The organic layer was washed with brine and concentrated in vacuo. The resulting solid was washed with ethanol-diethyl ether to give the title compound (3.53 g, 42%). 1H NMR (DMSO-d6) delta 3.56 (3H, s), 6.91 (1H, t, J = 8.0 Hz), 6.98 (1H, d, J = 8.0 Hz), 7.15 (1H, d, J = 8.0 Hz), 11.17 (1H, s).
26%		A mixture of 7-amino-l-methyl-l, 3-dihydro-2tf- benzimidazol-2-one (20.0 g, 122 mmol) and t-butyl nitrite(19.0 g, 184 mmol) in acetonitrile (500 mL) was stirred at room temperature for 30 min. The reaction mixture was cooled at O0C. To the mixture was added portionwise copper (I) bromide (19.3 g, 135 mmol). The mixture was stirred at room temperature for 18 h. To the reaction mixture was added saturated aqueous ammonium chloride solution (400 mL) . The mixture was filtered, and washed with methanol. The filtrate was concentrated in vacuo. The residue was dissolved in water and ethyl acetate. The organic layer was separated and the aqueous part was further extracted with ethyl acetate. The combined organics were dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography on basic silica gel eluting with a 50% ethyl acetate/hexane mixture to give the title compound (7.30 g, 26%) as a brown amorphous . 1H NMR (CDCl3) delta 3.55 (s, 3H), 6.90 (t, J = 8.1 Hz, IH), 6.97 (d, J = 8.1 Hz, IH), 7.14 (d, J = 8.1 Hz, IH), 11.2 (br, IH) .MS Calcd.: 226; Found: 227 (M+H) .

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691
[2]Patent: WO2008/51533,2008,A2 .Location in patent: Page/Page column 120

6
[ 913297-44-6 ]
[ 76513-69-4 ]
[ 1150102-49-0 ]

Yield	Reaction Conditions	Operation in experiment
		Compound 12C (454 mg, 2.0 mmol) was dissolved in DMF (10 mL) and the resulting solution was cooled to 0 C. NaH (88 mg, 2.2 mmol) was added carefully and the resulting reaction was stirred at 0 C for 10 minutes, then SEMCi (367 mg, 2.2 mmol) was added dropwise and the mixture was allowed to warm to room temperature on its own and stirred for about 15 hours. Saturated aqueous NH4CI solution was then added to quench the reaction and the mixture was extracted with EtOAc (40 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo and the resulting residue was purified using flash column chromatography (silica gel, 30% EtOAc/Hexanes) to provide compound 13A (688 mg) as oil. HPLC-MS tR = 2.32 min (UV254 nm); mass calculated for formula C14H2IBrN2O2Si 356.1 , observed LCMS m/z 329.1 (M+H - dimethyl).

Reference： [1]Patent: WO2009/58728,2009,A1 .Location in patent: Page/Page column 74

7
[ 913297-44-6 ]
[ 411235-57-9 ]
[ 1150102-48-9 ]

Yield	Reaction Conditions	Operation in experiment
		Compound 12C (363 mg, 1.6 mmol), K3PO4 (1.02 g, 4.8 mmol) and Pd(dppf)CI2 (5% mmol) were dissolved in 1 ,4 dioxane (5 mL) and the resulting solution was put under argon atmosphere. To this solution was added cyclopropane boronic acid (250 <n="76"/>mg, 2.9 mmol) and the reaction was heated to 90 C and allowed to stir at this temperature for 12 hours. The reaction mixture was diluted with EtOAc, washed sequentially with deionized water and brine, then dried over Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified using flash column chromatography (silica gel, ethyl acetate as eluent) to provide compound 12D as a white solid. HPLC-MS tR - 1.34 min (UV254 nm); mass calculated for formula C11H12N2O 188.1, observed LCMS m/z 189.1 (M+H).

Reference： [1]Patent: WO2009/58728,2009,A1 .Location in patent: Page/Page column 73; 73-74

8
[ 606-21-3 ]
[ 913297-44-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

9
[ 5910-19-0 ]
[ 913297-44-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

10
[ 60639-52-3 ]
[ 913297-44-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

11
[ 913297-44-6 ]
3-[(2-chloro-1-methyl-1H-benzimidazol-7-yl)amino]benzonitrile [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

12
[ 913297-44-6 ]
2-chloro-1-methyl-N-(1-methylethyl)-N-phenyl-1H-benzimidazol-7-amine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

13
[ 913297-44-6 ]
3-[(2-chloro-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]benzonitrile [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

14
[ 913297-44-6 ]
N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-phenyl-1H-benzimidazole-2,7-diamine [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

15
[ 913297-44-6 ]
methyl 3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]benzoate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

16
[ 913297-44-6 ]
3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]benzoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

17
[ 913297-44-6 ]
3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-N-methylbenzamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

18
[ 913297-44-6 ]
3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-N,N-dimethylbenzamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

19
[ 913297-44-6 ]
3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]benzonitrile [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

20
[ 913297-44-6 ]
3-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]benzamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

21
[ 913297-44-6 ]
[ 62-53-3 ]
7-anilino-1-methyl-1,3-dihydro-2H-benzimidazol-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
64%	With tris-(dibenzylideneacetone)dipalladium(0); sodium t-butanolate; XPhos; In 1,4-dioxane; at 100℃;Microwave irradiation;	General procedure: To a mixture of compound 5 (2.00 g, 12.3 mmol), X-Phos (0.292 g, 0.613 mmol), sodium tert-butoxide (2.94 g, 30.6 mmol) and tris(dibenzylidineacetone)dipalladium (0.224 g, 0.245 mmol) in 1,4-dioxane (25 mL) was added 4-bromoanisole (1.6 mL, 12.9 mmol) and heated to 100 C for 2 h. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and concentrated in vacuo. The residue was powdered from diethyl ether to give the title compound (2.02 g, 61%).

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

22
[ 913297-44-6 ]
[ 2237-30-1 ]
3-[(1-methyl-2-oxo-1,3-dihydro-2H-benzimidazol-7-yl)amino]benzonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
37%	With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; tris-(dibenzylideneacetone)dipalladium(0); sodium t-butanolate; In 1,4-dioxane;Reflux;	General procedure: To a mixture of compound 5 (0.300 g, 1.84 mmol), S-Phos (0.0377 g, 0.0919 mmol), sodium tert-butoxide (0.350 g, 3.70 mmol), tris(dibenzylidineacetone)dipalladium (0.170 g, 0.180 mmol) and 1,4-dioxane (0.5 mL) was added 4-bromophenylmethylsulfone (0.520 g, 2.20 mmol), and the mixture was refluxed for 4 h. The reaction mixture was cooled, poured into water, and extracted with ethyl acetate and ethyl acetate-tetrahydrofuran. The organic layer was concentrated in vacuo. The resulting solid was washed with ethyl acetate to give the title compound (0.357 g, 61%) as crystals.

Reference： [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4675 - 4691

23
[ 913297-44-6 ]
7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one [ No CAS ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

24
[ 913297-44-6 ]
7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one [ No CAS ]
C₁₃H₁₆N₂O [ No CAS ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

25
[ 913297-44-6 ]
7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one [ No CAS ]
C₁₃H₂₂N₂O [ No CAS ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

26
[ 913297-44-6 ]
[ 1022251-70-2 ]

27
[ 913297-44-6 ]
[ 913298-61-0 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[2]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[3]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[4]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[5]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[6]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[7]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[8]Organic Process Research and Development,2017,vol. 21,p. 222 - 230
[9]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

28
[ 913297-44-6 ]
4-chloro-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2Hbenzimidazol-2-one [ No CAS ]

29
[ 913297-44-6 ]
4-chloro-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2Hbenzimidazol-2-one [ No CAS ]
C₁₃H₁₇ClN₂O [ No CAS ]
C₁₃H₁₇ClN₂O [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]

30
[ 913297-44-6 ]
4-chloro-7-(1-ethylpropyl)-1-methyl-1,3-dihydro-2Hbenzimidazol-2-one [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]
C₁₃H₁₆Cl₂N₂O [ No CAS ]

31
[ 913297-44-6 ]
4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzo[d]imidazole [ No CAS ]

32
[ 913297-44-6 ]
[ 913299-73-7 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

33
[ 913297-44-6 ]
[ 96-22-0 ]
7-(1-ethyl-1-hydroxypropyl)-1-methyl-1,3-dihydro-2Hbenzimidazol-2-one [ No CAS ]
[ 1849-01-0 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

34
[ 20780-74-9 ]
[ 913297-44-6 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

35
[ 906660-35-3 ]
[ 913297-44-6 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

36
3-bromo-2-(methylamino)benzoic acid [ No CAS ]
[ 913297-44-6 ]

Reference： [1]Organic Process Research and Development,2017,vol. 21,p. 222 - 230

37
[ 913297-44-6 ]
2-chloro-1-methyl-7-(3-methyl-1H-pyrazol-1-yl)-1H-benzimidazole [ No CAS ]

Reference： [1]Patent: WO2006/116412,2006,A2

38
[ 913297-44-6 ]
2-chloro-7-(2-ethylphenyl)-1-methyl-1H-benzimidazole [ No CAS ]

Reference： [1]Patent: WO2006/116412,2006,A2

39
[ 913297-44-6 ]
N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(3-methyl-1H-pyrazol-1-yl)-1H-benzimidazol-2-amine [ No CAS ]

Reference： [1]Patent: WO2006/116412,2006,A2

40
[ 913297-44-6 ]
N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethylphenyl)-1-methyl-1H-benzimidazol-2-amine [ No CAS ]

Reference： [1]Patent: WO2006/116412,2006,A2

41
[ 913297-44-6 ]
N-(4-chloro-2-methoxy-6-methylphenyl)-7-(2-ethylphenyl)-1-methyl-2H-benzimidazol-2-amine trifluoroacetic acid salt [ No CAS ]

Reference： [1]Patent: WO2006/116412,2006,A2

42
[ 913297-44-6 ]
[ 913297-45-7 ]

Reference： [1]Patent: WO2006/116412,2006,A2

43
[ 1004618-77-2 ]
[ 913297-44-6 ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

44
[ 1150102-47-8 ]
[ 913297-44-6 ]

Yield	Reaction Conditions	Operation in experiment
88%	With 1,1'-carbonyldiimidazole; In acetonitrile; at 85℃; for 12.0h;Inert atmosphere;	To a mixture of 3-bromo-N2-methyl-benzene-1,2-diamine (20.0 g, 99.4 mmol) in ACN (300 mL) was added CDI (32.2 g, 198 mmol). The reaction mixture was stirred at 85 C. for 12 hours under N2 atmosphere. On completion, the reaction mixture was concentrated in vacuo. The reaction mixture was diluted with water (200 mL), where a solid precipitate was formed, which was filtered off. The solid was washed with water (1 L) and dried in vacuo to give the title compound (20.0 g, 88% yield) as white solid. 1H NMR (400 MHz, DMSO-d6) delta 11.17 (s, 1H), 7.14 (dd, J=1.2, 8.0 Hz, 1H), 7.00-6.95 (m, 1H), 6.93-6.87 (m, 1H), 3.55 (s, 3H).

Reference： [1]Patent: US2019/192668,2019,A1 .Location in patent: Paragraph 2881; 2884

45
[ 913297-44-6 ]
3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

46
[ 913297-44-6 ]
tert-butyl (2-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

47
[ 913297-44-6 ]
tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethoxy]ethyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

48
[ 913297-44-6 ]
3-[4-[3-[2-(2-aminoethoxy)ethoxy]propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

49
[ 913297-44-6 ]
3-[4-[3-[2-(2-hydroxyethoxy)ethoxy]prop-1-ynyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

50
[ 913297-44-6 ]
3-[4-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

51
[ 913297-44-6 ]
2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethoxy]acetaldehyde [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

52
[ 913297-44-6 ]
tert-butyl N-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]prop-2-yn-1-yl]oxy)propyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

53
[ 913297-44-6 ]
tert-butyl N-(3-[3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]propoxy]propyl)carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

54
[ 913297-44-6 ]
tert-butyl N-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]prop-2-yn-1-yl]oxy)propoxy]propyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

55
[ 913297-44-6 ]
tert-butyl N-[3-(3-[3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]propoxy]propoxy)propyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

56
[ 913297-44-6 ]
tert-butyl N-[4-([4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]but-3-yn-1-yl]oxy)butyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

57
[ 913297-44-6 ]
tert-butyl N-(4-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]butoxy]butyl)carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

58
[ 913297-44-6 ]
tert-butyl N-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]prop-2-yn-1-yl]oxy)-2,2-dimethylpropoxy]propyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

59
[ 913297-44-6 ]
tert-butyl N-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

60
[ 913297-44-6 ]
tert-butyl N-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

61
[ 913297-44-6 ]
3-[4-(3-aminopropyl)-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

62
[ 913297-44-6 ]
(E)-3-(4-(3-hydroxyprop-1-en-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

63
[ 913297-44-6 ]
3-(4-(3-hydroxypropyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

64
[ 913297-44-6 ]
3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)propanal [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

65
[ 913297-44-6 ]
3-(4-(3-(((6-(aminomethyl)hexahydrofuro[3,2-b]furan-3-yl)methyl)amino)propyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

66
[ 913297-44-6 ]
3-[3-methyl-4-[3-[3-(methylamino)propoxy]propyl]-2-oxobenzimidazol-1-yl]piperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

67
[ 913297-44-6 ]
tert-butyl N-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynoxy]ethyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

68
[ 913297-44-6 ]
tert-butyl N-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

69
[ 913297-44-6 ]
3-[4-[3-(2-aminoethoxy)propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

70
[ 913297-44-6 ]
tert-butyl N-[[(2R)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-5-yl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

71
[ 913297-44-6 ]
tert-butyl N-[[(2R)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-5-yl]propyl]morpholin-2-yl]methyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

72
[ 913297-44-6 ]
3-[5-[3-[(2R)-2-(aminomethyl)morpholin-4-yl]propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

73
[ 913297-44-6 ]
tert-butyl 2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethoxy]acetate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

74
[ 913297-44-6 ]
tert-butyl 2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethoxy]acetate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

75
[ 913297-44-6 ]
2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethoxy]acetic acid [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

76
[ 913297-44-6 ]
tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethyl]-N-methylcarbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

77
[ 913297-44-6 ]
tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propoxy]ethoxy]ethyl]-N-methylcarbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

78
[ 913297-44-6 ]
3-[3-methyl-4-[3-[2-[2-(methylamino)ethoxy]ethoxy]propyl]-2-oxobenzimidazol-1-yl]piperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

79
[ 913297-44-6 ]
tert-butyl N-[[(2R)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propyl]morpholin-2-yl]methyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

80
[ 913297-44-6 ]
3-[4-[3-[(2R)-2-(aminomethyl)morpholin-4-yl]propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidin-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

81
[ 913297-44-6 ]
tert-butyl N-[[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

82
[ 913297-44-6 ]
tert-butyl N-[[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]propyl]morpholin-2-yl]methyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

83
[ 913297-44-6 ]
(x)C₂HF₃O₂*C₂₁H₂₉N₅O₄ [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

84
[ 913297-44-6 ]
3-(4-bromo-3-methyl-2-oxobenzimidazol-1-yl)-1-methylpiperidine-2,6-dione [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

85
[ 913297-44-6 ]
tert-butyl N-[2-[2-[3-[3-methyl-1-(1-methyl-2,6-dioxo-3-piperidyl)-2-oxobenzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

86
[ 913297-44-6 ]
tert-butyl N-[2-[2-[3-[3-methyl-1-(1-methyl-2,6-dioxo-3-piperidyl)-2-oxobenzimidazol-4-yl]propoxy]ethoxy]ethyl]carbamate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

87
[ 913297-44-6 ]
3-[4-[3-[2-(2-aminoethoxy)ethoxy]propyl]-3-methyl-2-oxobenzimidazol-1-yl]-1-methylpiperidine-2,6-dione hydrochloride [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1

88
[ 913297-44-6 ]
tert-butyl 4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynoxy]piperidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2019/192668,2019,A1
[2]Patent: WO2020/113233,2020,A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 913297-44-6 ]

Bromides

[ 1240593-33-2 ]

4-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 1.00

[ 1644148-81-1 ]

4,6-Dibromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.98

[ 24786-52-5 ]

5-Amino-6-bromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.96

[ 40644-16-4 ]

4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.93

[ 305790-48-1 ]

6-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.91

Amides

[ 1240593-33-2 ]

4-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 1.00

[ 1644148-81-1 ]

4,6-Dibromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.98

[ 24786-52-5 ]

5-Amino-6-bromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.96

[ 40644-16-4 ]

4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.93

[ 305790-48-1 ]

6-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.91

Related Parent Nucleus of
[ 913297-44-6 ]

Benzimidazoles

[ 1240593-33-2 ]

4-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 1.00

[ 1644148-81-1 ]

4,6-Dibromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.98

[ 24786-52-5 ]

5-Amino-6-bromo-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.96

[ 40644-16-4 ]

4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.93

[ 305790-48-1 ]

6-Bromo-1-methyl-1H-benzo[d]imidazol-2(3H)-one

Similarity: 0.91

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 913297-44-6 ] {[proInfo.proName]}

Quality Control of [ 913297-44-6 ]

Related Doc. of [ 913297-44-6 ]

Product Details of [ 913297-44-6 ]

Safety of [ 913297-44-6 ]

Application In Synthesis of [ 913297-44-6 ]

[ 913297-44-6 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 913297-44-6 ]

Bromides

Amides

Related Parent Nucleus of [ 913297-44-6 ]

Benzimidazoles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 913297-44-6 ]

Related Parent Nucleus of
[ 913297-44-6 ]